Get started
Author

Urbano Anido

Observed names: Anido, Urbano, U Anido, U. ANIDO-HERRANZ, U. Anido, U. Anido Herranz, U. Anido-Herranz, Urbano Anido Herranz, Urbano Anido-Herranz
Observed institutions: Universitat Autònoma de Barcelona, Universidade de Santiago de Compostela, Complejo Hospitalario Universitario de Santiago, Centro Oncológico de Galicia, Vall d'Hebron Institut de Recerca, Povisa Hospital, Complexo Hospitalario Universitario A Coruña, Instituto de Investigación Sanitaria de Santiago, Hospital Universitario De Cabueñes, Servicio Gallego de Salud, Hospital Xeral Calde, Centro de Investigación Biomédica en Red de Cáncer, Complejo Hospitalario de Ourense
ORCID: 0000-0003-0376-5642
Observed ORCID: 0000-0003-0376-5642
OpenAlex ID: A5077458179
Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial
2019 · Thomas Powles, Mark Kockx, et al. · Nature Medicine · 591
PDF
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial
2020 · Thomas Powles, Michiel S van der Heijden, et al. · The Lancet Oncology · 501
PDF
Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder
2022 · Bernadett Szabados, Mark Kockx, et al. · European Urology · 210
PDF
Evaluation of Circulating Tumor Cells and Related Events as Prognostic Factors and Surrogate Biomarkers in Advanced NSCLC Patients Receiving First-Line Systemic Treatment
2014 · Laura Muinelo-Romay, Maria Vieito, et al. · Cancers · 107
PDF
Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial
2017 · Jesus García-Donas, Albert Font, et al. · The Lancet Oncology · 50
Phase 3 KEYNOTE-361 trial: Pembrolizumab (pembro) with or without chemotherapy versus chemotherapy alone in advanced urothelial cancer.
2017 · Thomas Powles, Juergen E. Gschwend, et al. · Journal of Clinical Oncology · 47
Rethinking prognostic factors in locally advanced or metastatic urothelial carcinoma in the immune checkpoint blockade era: a multicenter retrospective study
2021 · J. Ruiz-Bañobre, A. Molina-Díaz, et al. · ESMO Open · 46
PDF
High-Risk Endometrial Carcinoma Profiling Identifies TGF-β1 as a Key Factor in the Initiation of Tumor Invasion
2011 · Laura Muinelo-Romay, Eva Colas, et al. · Molecular Cancer Therapeutics · 41
Clinical potential of circulating free DNA and circulating tumour cells in patients with metastatic non‐small‐cell lung cancer treated with pembrolizumab
2021 · Patricia Mondelo‐Macía, Jorge García‐González, et al. · Molecular Oncology · 36
PDF
X-Ray Cross-Complementing Group 1 and Thymidylate Synthase Polymorphisms Might Predict Response to Chemoradiotherapy in Rectal Cancer Patients
2010 · Maria J. Lamas, Goretti Duran, et al. · International Journal of Radiation Oncology*Biology*Physics · 36
Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study
2013 · C de la Piedra, A Alcaraz, et al. · British Journal of Cancer · 34
PDF
Toxicity and Surgical Complication Rates of Neoadjuvant Atezolizumab in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy: Updated Safety Results from the ABACUS Trial
2021 · Bernadett Szabados, Alejo Rodriguez-Vida, et al. · European Urology Oncology · 32
Pazopanib: Evidence review and clinical practice in the management of advanced renal cell carcinoma
2018 · María José Méndez-Vidal, Áurea Molina, et al. · BMC Pharmacology and Toxicology · 31
PDF
Evaluation of 177Lu-Dotatate treatment in patients with metastatic neuroendocrine tumors and prognostic factors
2020 · Estephany Abou Jokh Casas, Virginia Pubul Núñez, et al. · World Journal of Gastroenterology · 27
PDF
Development of de novo psoriasis during nivolumab therapy for metastatic renal cell carcinoma: immunohistochemical analyses and clinical outcome
2017 · Juan Ruiz‐Bañobre, Ihab Abdulkader, et al. · Apmis · 25
Improving circulating tumor cells enumeration and characterization to predict outcome in first line chemotherapy mCRPC patients
2017 · Luis León-Mateos, Helena Casas, et al. · Oncotarget · 24
PDF
A logistic model for the detection of circulating tumour cells in human metastatic colorectal cancer
2012 · Jorge Barbazán, María Vieito, et al. · Journal of Cellular and Molecular Medicine · 23
PDF
Weekly cabazitaxel plus prednisone is effective and less toxic for ‘unfit’ metastatic castration-resistant prostate cancer: Phase II Spanish Oncology Genitourinary Group (SOGUG) trial
2017 · Miguel Ángel Climent, Begoña Pérez-Valderrama, et al. · European Journal of Cancer · 21
A randomized phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium (SECAVIN)
2017 · J. Bellmunt, J.M. Kerst, et al. · Annals of Oncology · 21
Everolimus safety and efficacy for renal angiomyolipomas associated with tuberous sclerosis complex: a Spanish expanded access trial
2016 · Nicolás Roberto Robles, Ramón Peces, et al. · Orphanet Journal of Rare Diseases · 20
PDF
Global Gene Expression Characterization of Circulating Tumor Cells in Metastasic Castration-Resistant Prostate Cancer Patients
2020 · Luis León-Mateos, Alicia Abalo, et al. · Journal of Clinical Medicine · 19
PDF
Severe hypertension and hypokalemia as first clinical manifestations in ectopic Cushing's syndrome
2008 · Eva Fernández-Rodríguez, Rocío Villar-Taibo, et al. · Arquivos Brasileiros de Endocrinologia & Metabologia · 19
PDF
Long-term Response to Nivolumab and Acute Renal Failure in a Patient with Metastatic Papillary Renal Cell Carcinoma and a PD-L1 Tumor Expression Increased with Sunitinib Therapy: A Case Report
2016 · Juan Ruiz-Bañobre, Urbano Anido, et al. · Frontiers in Oncology · 17
PDF
Clinical Application of Circulating Tumour Cells in Prostate Cancer: From Bench to Bedside and Back
2016 · Luis León-Mateos, María Vieito, et al. · International Journal of Molecular Sciences · 17
PDF
Longitudinal CTCs gene expression analysis on metastatic castration-resistant prostate cancer patients treated with docetaxel reveals new potential prognosis markers
2021 · Thais Pereira-Veiga, Miriam González-Conde, et al. · Clinical & Experimental Metastasis · 15
PDF
Works count: 169
Citation count: 2,314
H-index: 20
I10-index: 33
Year
Topic
Type